ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2017

Jan 9, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2017-01-06

Reporting Person: SOUTHWELL DAVID P (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-06	Common Stock	P	60000	$1.75	Acquired	62765	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.749 to $1.75, inclusive. The reporting person undertakes to provide to Inotek Pharmaceuticals Corporation, any security holder of Inotek Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F2: Includes 2,765 shares of the Issuer's common stock acquired under the Issuer's Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 with Table I Information.